Brooke: Dengvaxia and Dengue Virus Study Notes

Introduction to Dengvaxia

  • Dengvaxia is the first licensed therapeutic dengue vaccine on the market.

Dengue Virus Overview

General Characteristics

  • Dengue virus is a positive sense RNA virus within the family of flaviviruses.

  • Related viruses include West Nile virus, yellow fever virus, and others.

Genome Structure

  • The dengue virus genome consists of:   - Structural Proteins:     - Capsid proteins     - Membrane proteins     - Envelope proteins   - Nonstructural Proteins:     - Important for viral replication, receptor binding, co-localization, and budding during replication.

Transmission

Arbovirus Classification

  • Dengue is classified as an arbovirus.

  • Transmitted primarily through Aedes aegypti mosquitoes:   - Mosquitoes serve as replication-competent hosts, allowing the virus to be transmitted during blood meals.

  • Alternative transmission routes:   - Blood transfusions   - Rarely through organ transplants.

Symptoms of Dengue Infection

Common Symptoms

  • Known as "bone break fever" due to severe musculoskeletal pain.

  • Symptoms can range from asymptomatic to severe including:   - High fever   - Severe muscle pain   - Joint pain   - Eye pain   - Headaches

Severe Forms

  • Severe cases may lead to:   - Dengue shock syndrome   - Hemorrhagic fever

  • Higher severity risk in patients with prior dengue infections due to multiple serotypes.

Clinical Progression of Dengue Infection

Timeline of Infection

  1. Incubation Period:    - Lasts 4-10 days (average ~7 days).    - No symptoms during this time.

  2. Febrile Phase:    - Initial onset of symptoms coincides with viremia phase.    - Virus replicates leading to high viral levels in the bloodstream.    - Infectious to new mosquitoes during this phase.

  3. Critical Phase:    - Occurs after fever subsides.    - Risk of severe complications peaks.

  4. Recovery Phase:    - Most individuals recover, but pediatric patients are at higher risk.

Public Health Impact

Prevalence and Mortality

  • 3.6 million cases reported in 2025.

  • Approximately 1900 deaths due to dengue-related illnesses.

  • Dengue is endemic across 97 countries, predominantly in:   - Brazil   - Eastern Mediterranean   - Asia

Contributing Factors to Surge in Infections

  • Changes in mosquito habitats due to:   - Deforestation   - Urbanization   - Global warming.

  • Increased vectorial range due to habitat alterations.

Diagnosis and Treatment

Diagnostic Methods

  1. Early Detection (1-2 days post-symptom onset):    - qPCR assay: Amplifies viral RNA from patient blood samples.    - Determines the serotype and viral load.

  2. Late Detection:    - ELISA testing: Detects antibodies to all four serotypes from serum samples.

Treatment Approaches

  • No specific antivirals for dengue.

  • Focus on supportive care:   - Hydration   - Pain management.

Prevention Strategies

  • Vector control:   - Elimination of standing water.   - Use of insect repellents and protective clothing.   - Environmental management.

Historical Context of Dengue

Disease Origin and Timeline

  • Earliest reference: Bone break fever documented in 1780.

  • First isolate: 1940, linked to Aedes aegypti in 1903.

  • Notable events:   - 1947: Successful mosquito eradication campaign in the Americas.   - Emergence of dengue hemorrhagic fever in 1950s.   - First re-emergence in North America in 1981 (dengue serotype 4).   - 2001-2008: Peak of over a million reported cases.

Dengue Vaccine Development

Challenges in Vaccine Development

  • Multiple dengue serotypes necessitate protection against all four simultaneously.

  • Rapid viral replication complicates treatment windows.

  • Immune response variability complicates treatment especially during secondary infections.

Dengvaxia Vaccine Overview

Characteristics

  • Developed by Sanofi and licensed in 2015.

  • A live attenuated tetravalent vaccine.

  • Built on a yellow fever virus backbone, replacing the surface proteins with dengue serotype proteins.

Mechanism of Action

  • Mimics natural infection without causing disease.

  • Activation of innate immune responses and production of neutralizing antibodies across all four serotypes.

Clinical Trials and Efficacy

Trial Design

  • Conducted in Asia (and Brazil concurrently):   - Randomized, observer-blind, placebo-controlled.   - Patients monitored for six years post-vaccination.

Findings

  • Incidence rates showed potential increased risk for seronegative individuals:   - Example: 9-year-olds had 50% higher risk of hospitalization among vaccinated compared to control.

  • Study results published in NEJM raised concerns about serious adverse effects on seronegative individuals.

Regulatory and Ethical Concerns

Aftermath of Clinical Results

  • Despite safety concerns, vaccination campaigns launched in the Philippines.

  • October 2016: WHO recommended further investigation into the safety of the vaccine due to rising complications.

  • Significant public backlash and loss of trust in vaccines.

  • 2017: Reports of severe dengue cases and 10 associated child deaths from vaccination.

Subsequent Regulatory Changes

  • Recommendations for serological testing prior to vaccination.

  • Required extensive monitoring of vaccine recipients.

  • Stronger safety warnings and long-term follow-up mandated by WHO.

Conclusion and Future Perspectives

Key Takeaways

  • Dengue remains complex with multiple serotypes contributing to severe outcomes influenced by immune response.

  • The rapid replication of the virus complicates treatment efforts.

  • Dengvaxia was eventually removed from the market due to safety concerns.

Advances in Vaccine Development

  • Newer vaccine, Quadega developed by Takeda, aims to address the shortcomings of Dengvaxia and is designed to be effective irrespective of prior infection status.

  • Current phase III trials may offer better solutions to controlling dengue in endemic regions.

Questions and Community Discussions

  • Ongoing discussions regarding public perception, regulatory processes, and ethical considerations in vaccine trials, especially in developing nations.